Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: Detection of homologous and heterologous neutralizing antibody to subtype E (CRF01.AE) HIV type 1

AIDS Research and Human Retroviruses

Volumn 19, Issue 9, 2003, Pages 807-816

  Kim, Jerome H ^a,f   Pitisuttithum, Punnee ^b   Kamboonruang, Chirasak ^c   Chuenchitra, Thippawan ^d   Mascola, John ^a   Frankel, Sarah S ^a   DeSouza, Mark S ^d   Polonis, Victoria ^a   McLinden, Robert ^a   Sambor, Anna ^a   Brown, Arthur E ^d   Phonrat, Benjaluck ^b   Rungruengthanakit, Kittipong ^c   Duliege, Anne Marie ^e   Robb, Merlin L ^a   McNeil, John ^a   Birx, Deborah L ^a  

^a US Military HIV Research Program   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^e NOVARTIS PHARMA AG   (Switzerland)

^f TRIPLER ARMY MEDICAL CENTER   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CELL LINE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; T LYMPHOCYTE; VACCINATION; VIROGENESIS; VIRUS TITRATION;

EID: 0141705296     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203769232601     Document Type: Article

References (50)

1. World Health Organization: Global AIDS surveillance. Wkly Epidemiol Rep 1998;73:373-376.
2. Quinn TC: Global burden of the HIV pandemic. Lancet 1996;348:99-106.
3. UNAIDS: Epidemiological Fact Sheet on HIV/AIDS and Sexually Transmitted Infections: Thailand: 2000 Update, 2000.
4. Nelson KE, Celentano DD, Eiumtrakol S, et al.: Changes in sexual behavior and a decline in HIV infection among young men in Thailand. N Engl J Med 1996;335:297-303.
5. Berman PW, Matthews TJ, Riddle L, et al.: Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J Virol 1992;66:4464-4469.
6. Belshe RB, Clements ML, Dolin R, et al.: Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. J Infect Dis 1993;168:1387-1395.
7. Belshe RB, Graham BS, Keefer MC, et al.: Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. JAMA 1994;272:475-480.
8. Gorse GJ, Corey L, Patel GB, et al.: HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1999;15:115-132.
9. Gorse GJ, McElrath MJ, Matthews TJ, et al.: Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Vaccine 1998;16:493-506.
10. Gorse GJ, Frey SE, Patel G, Newman FK, and Belshe RB: Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network. Vaccine 1994; 12:912-918.
11. Graham BS, Keefer MC, McElrath MJ, et al.: Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann Intern Med 1996;125:270-279.
12. Girard MP and Excler JL: Human immunodeficiency virus. In: Vaccines (Plotkin SA and Orenstein WA, eds.), 3rd Ed. W.B. Saunders, Philadelphia, Pennsylvania, 1999 pp. 928-967.
13. Keefer MC, Graham BS, Belshe RB, et al.: Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network. AIDS Res Hum Retroviruses 1994;10:1713-1723.
14. Keefer MC, Graham BS, McElrath MJ, et al.: Safety and immunogenicity of env 2-3, a human immunodeficiency vires type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. AIDS Res Human Retroviruses 1996;12:683-693.
15. Schwartz DH, Gorse G, Clements ML, et al.: Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. Lancet 1993;342:69-73.
16. Nitayaphan S, Khamboonruang C, Sirisophana N, et al.: A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. Vaccine 2000;18:1448-1455.
17. Migasena S, Suntharasamai P, Pitisuttithum P, et al.: AIDSVAX (MN) in Bangkok injecting drug users: A report on safety and immunogenicity, including macrophage-tropic virus neutralization. AIDS Res Hum Retroviruses 2000;16:655-663.
18. Mascola JR, Snyder SW, Weislow OS, et al.: Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996;173:340-348.
19. Zolla-Pazner S, Alving C, Belshe R, et al.: Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines. J Infect Dis 1997;175:764-774.
20. VanCott TC, Bethke FR, Burke DS, Redfield RR, and Birx DL: Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J Immunol 1995;155:4100-4110.
21. Earl PL, Broder CC, Long D, et al.: Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 1994;68:3015-3026.
22. Broder CC, Earl PL, Long D, Abedon ST, Moss B, and Doms RW: Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: Oligomer-specific and-sensitive monoclonal antibodies. Proc Natl Acad Sci USA 1994;91:11699-11703.
23. Robertson DL, Anderson JP, Bradac JA, et al.: HIV-1 nomenclature proposal. Science 2000;288:55-57.
24. VanCott TC, Mascola JR, Loomis-Price LD, et al.: Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope. J Virol 1999;73:4640-4650.
25. Berman PW, Huang W, Riddle L, et al.: Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. Virology 1999;265:1-9.
26. Ou CY, Takebe Y, Luo CC, et al.: Wide distribution of two subtypes of HIV-1 in Thailand. AIDS Res Hum Retroviruses 1992;8:1471-1472.
27. McCutchan FE, Hegerich PA, Brennan TP, et al.: Genetic variants of HIV-1 in Thailand. AIDS Res Hum Retroviruses 1992;8:1887-1895.
28. Limpakarnjanarat K, Ungchusak K, Mastro TD, et al.: The epidemiological evolution of HIV-1 subtypes B and E among heterosexuals and injecting drug users in Thailand, 1992-1997 [letter]. AIDS 1998;12:1108-1109.
29. Moore JP, Cao Y, Leu J, Qin L, Korber B, and Ho DD: Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996;70:427-444.
30. Kostrikis LG, Cao Y, Ngai H, Moore JP, and Ho DD: Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 1996;70:445-458.
31. Mascola JR, Louwagie J, McCutchan FE, et al.: Two antigenically distinct subtypes of human immunodeficiency virus type 1: Viral genotype predicts neutralization serotype. J Infect Dis 1994;169:48-54.
32. Mascola JR: Neutralization of HIV-1 infection of human peripheral blood mononuclear cells (PBMC): Antibody dilution method. In: HIV Protocols (Michael NL and Kim JH, eds.), Vol. 17. Humana Press, Totowa, New Jersey, 1999, pp. 309-315.
33. Frankel SS, Steinman RM, Michael NL, et al.: Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. J Virol 1998;72:9788-9794.
34. Pitisuttihum P, Nitayaphan S, Thongoharoen P, et al. Safety of an immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccine in healthy Thai adults. J Infect Dis 2003;188:219-227.
35. Trkola A, Matthews J, Gordon C, Ketas T, and Moore JP. A cell line based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol 1999;73:8966-8974.
36. Stamatos NM, Mascola JR, Kalyanaraman VS, et al.: Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. J Virol 1998;72:9656-9667.
37. Steimer KS, Scandella CJ, Skiles PV, and Haigwood NL: Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science 1991;254:105-108.
38. Lee SA, Orque R, Escarpe PA, et al.: Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates. Vaccine 2002;20:563-576.
39. Verrier F, Burda S, Belshe R, et al.: A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4, R5 and dual tropic clade B and C primary isolates. J Virol 2000;74:10025-10033.
40. VanCott TC, Mascola JR, Kaminski RW, et al.: Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J Virol 1997;71:4319-4330.
41. VanCott TC, Kaminski RW, Mascola JR, et al.: HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J Immunol 1998;160:2000-2012.
42. Sattentau QJ and Moore JP: Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med 1995;182:185-196.
43. Bou-Habib DC, Roderiquez G, Oravecz T, Berman PW, Lusso P, and Norcross MA: Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994;68:6006-6013.
44. Sullivan N, Sun Y, Li J, Hofmann W, and Sodroski J: Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol 1995;69:4413-4422.
45. Vancott TC, Polonis VR, Loomis LD, Michael NL, Nara PL, and Birx DL: Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses 1995;11:1379-1391.
46. Wrin T, Loh TP, Vennari JC, Schuitemaker H, and Nunberg JH: Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol 1995;69:39-48.
47. Berman PW: Development of bivalent rgp 120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retroviruses 1998;14:S277-S289.
48. Steimer KS, Sakamoto D, Yi DS, West D, Baenziger J, and Sinangil F: Primary isolate neutralizing activity of human antibodies directed to recombinant, native HIV-1 SF2 gp120 (rgp120SF2) [Abstract]. J Cell Biochem 1994;18B:114.
49. Kliks SC, Shioda T, Haigwood NL, and Levy JA: V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90:11518-11522.
50. Cohen J: AIDS vaccine trial produces disappointment and confusion. Science 2003;299:1290-1291.